Target Price | $55.20 |
Price | $30.25 |
Potential |
82.48%
register free of charge
|
Number of Estimates | 5 |
5 Analysts have issued a price target Monopar Therapeutics Inc 2026 .
The average Monopar Therapeutics Inc target price is $55.20.
This is
82.48%
register free of charge
$72.00
138.02%
register free of charge
$37.00
22.31%
register free of charge
|
|
A rating was issued by 5 analysts: 5 Analysts recommend Monopar Therapeutics Inc to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Monopar Therapeutics Inc stock has an average upside potential 2026 of
82.48%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -3.04 | -0.58 |
26.39% | 80.92% | |
P/E | negative |
1 Analysts have issued a Monopar Therapeutics Inc forecast for earnings per share. The average Monopar Therapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Monopar Therapeutics Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 22 2025 |
Piper Sandler | Locked ➜ Locked | Locked | Jan 10 2025 |
HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 11 2024 |
Rodman & Renshaw | Locked ➜ Locked | Locked | Oct 11 2024 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 22 2025 |
Locked
Piper Sandler: Locked ➜ Locked
|
Jan 10 2025 |
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 11 2024 |
Locked
Rodman & Renshaw: Locked ➜ Locked
|
Oct 11 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.